{"id":2740,"date":"2020-05-22T09:26:22","date_gmt":"2020-05-22T09:26:22","guid":{"rendered":"https:\/\/mmevost.wpenginepowered.com\/success-stories\/bioithas-sclerotest\/"},"modified":"2025-11-25T13:23:15","modified_gmt":"2025-11-25T13:23:15","slug":"bioithas-sclerotest","status":"publish","type":"success-stories","link":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/","title":{"rendered":"Bioithas \u2013 ScleroTest"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"<p>La Esclerosis M\u00faltiple (EM) es una enfermedad cr\u00f3nica del sistema nervioso central. La EM afecta a m\u00e1s de 2,5 millones de personas en el mundo, siendo uno de los trastornos neurol\u00f3gicos m\u00e1s comunes en adultos j\u00f3venes. Por otro lado, produce un alto impacto socioecon\u00f3mico&#8230;<\/p>\n","protected":false},"featured_media":2292,"template":"","meta":{"_acf_changed":false},"flags":[102],"program":[46],"sector":[36],"class_list":["post-2740","success-stories","type-success-stories","status-publish","has-post-thumbnail","hentry","flags-es","program-instrumento-pyme-eic-accelerator","sector-salud"],"acf":{"layouts_cases":[{"acf_fc_layout":"content","content":{"sections_settings":{"section_id":"","section_background":false,"section_padding":"base"},"content":"La Esclerosis M\u00faltiple (EM) es una enfermedad cr\u00f3nica del sistema nervioso central. La EM afecta a m\u00e1s de 2,5 millones de personas en el mundo, siendo uno de los trastornos neurol\u00f3gicos m\u00e1s comunes en adultos j\u00f3venes. Por otro lado, produce un alto impacto socioecon\u00f3mico en el continente europeo, ya que representa uno de los problemas de salud p\u00fablica m\u00e1s relevantes (con un coste anual de 15,5 billones de euros en Europa).\r\n\r\nA pesar de ello, a\u00fan no existe cura para la EM, y las terapias no siempre conllevan una mejora por parte del paciente. Aplicar tratamientos personalizados resulta crucial para tratar esta enfermedad, pero la falta de biomarcadores predictivos y la imposibilidad de adaptar los resultados cl\u00ednicos a cada paciente, hace que sea muy complicado lograr una soluci\u00f3n.\r\n\r\nEn este contexto, <a href=\"https:\/\/www.bioithas.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Bioithas<\/a>, compa\u00f1\u00eda biotecnol\u00f3gica del sector de la salud, ha desarrollado ScleroTest, el primer biomarcador basado en microbiota para predecir una mejor respuesta al tratamiento de la EM. Dicho proyecto consiste en una prueba de diagn\u00f3stico r\u00e1pida, no invasiva y precisa para pronosticar la posible respuesta del paciente a un tratamiento temprano. ScleroTest busca, como resultado final, la posibilidad de implementar terapias personalizadas para combatir la EM, con un alto valor a\u00f1adido para pacientes, neur\u00f3logos y sistemas de salud.\r\n\r\nScleroTest no solo representa una mejora en el estudio de la Esclerosis M\u00faltiple, sino que tambi\u00e9n podr\u00eda implementarse en terapias para otras enfermedades. Por ello, Bioithas contin\u00faa desarrollando biomarcadores predictivos y productos probi\u00f3ticos para conseguir una mejora en la calidad de vida y en la salud de las personas a trav\u00e9s de la investigaci\u00f3n cient\u00edfica.\r\n\r\n<a href=\"https:\/\/evolutioneurope.eu\/es\/blog\/biotecnologia-espana-bioithas\/\" target=\"_blank\" rel=\"noopener\">\r\nLee la entrevista aqu\u00ed <\/a>"}},{"acf_fc_layout":"media","media":{"sections_settings":{"section_id":"","section_background":false,"section_padding":"base"},"intro":"","section_type":"image","image":4244,"video_type":"mp4","upload_video":"","video_id":"","video_placeholder":"","video_title":"","button":null}}],"layouts":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bioithas \u2013 ScleroTest - evolution-europe<\/title>\n<meta name=\"description\" content=\"La Esclerosis M\u00faltiple (EM) es una enfermedad cr\u00f3nica del sistema nervioso central. La EM afecta a m\u00e1s de 2,5 millones de personas en el mundo, siendo uno de los trastornos neurol\u00f3gicos m\u00e1s comunes en adultos j\u00f3venes. Por otro lado, produce un alto impacto socioecon\u00f3mico...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bioithas \u2013 ScleroTest\" \/>\n<meta property=\"og:description\" content=\"La Esclerosis M\u00faltiple (EM) es una enfermedad cr\u00f3nica del sistema nervioso central. La EM afecta a m\u00e1s de 2,5 millones de personas en el mundo, siendo uno de los trastornos neurol\u00f3gicos m\u00e1s comunes en adultos j\u00f3venes. Por otro lado, produce un alto impacto socioecon\u00f3mico...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/\" \/>\n<meta property=\"og:site_name\" content=\"evolution-europe\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T13:23:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/bioithas_featured_.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/bioithas-sclerotest\\\/\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/bioithas-sclerotest\\\/\",\"name\":\"Bioithas \u2013 ScleroTest - evolution-europe\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/bioithas-sclerotest\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/bioithas-sclerotest\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/bioithas_featured_.jpg\",\"datePublished\":\"2020-05-22T09:26:22+00:00\",\"dateModified\":\"2025-11-25T13:23:15+00:00\",\"description\":\"La Esclerosis M\u00faltiple (EM) es una enfermedad cr\u00f3nica del sistema nervioso central. La EM afecta a m\u00e1s de 2,5 millones de personas en el mundo, siendo uno de los trastornos neurol\u00f3gicos m\u00e1s comunes en adultos j\u00f3venes. Por otro lado, produce un alto impacto socioecon\u00f3mico...\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/bioithas-sclerotest\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/bioithas-sclerotest\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/bioithas-sclerotest\\\/#primaryimage\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/bioithas_featured_.jpg\",\"contentUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/bioithas_featured_.jpg\",\"width\":800,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/bioithas-sclerotest\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Success stories\",\"item\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bioithas \u2013 ScleroTest\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\",\"name\":\"evolution-europe\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#organization\",\"name\":\"Evolution Europe\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/social-share-image-2000x1600-1.jpg\",\"contentUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/social-share-image-2000x1600-1.jpg\",\"width\":2000,\"height\":1600,\"caption\":\"Evolution Europe\"},\"image\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bioithas \u2013 ScleroTest - evolution-europe","description":"La Esclerosis M\u00faltiple (EM) es una enfermedad cr\u00f3nica del sistema nervioso central. La EM afecta a m\u00e1s de 2,5 millones de personas en el mundo, siendo uno de los trastornos neurol\u00f3gicos m\u00e1s comunes en adultos j\u00f3venes. Por otro lado, produce un alto impacto socioecon\u00f3mico...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/","og_locale":"es_ES","og_type":"article","og_title":"Bioithas \u2013 ScleroTest","og_description":"La Esclerosis M\u00faltiple (EM) es una enfermedad cr\u00f3nica del sistema nervioso central. La EM afecta a m\u00e1s de 2,5 millones de personas en el mundo, siendo uno de los trastornos neurol\u00f3gicos m\u00e1s comunes en adultos j\u00f3venes. Por otro lado, produce un alto impacto socioecon\u00f3mico...","og_url":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/","og_site_name":"evolution-europe","article_modified_time":"2025-11-25T13:23:15+00:00","og_image":[{"width":800,"height":800,"url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/bioithas_featured_.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/","url":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/","name":"Bioithas \u2013 ScleroTest - evolution-europe","isPartOf":{"@id":"https:\/\/evolutioneurope.eu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/#primaryimage"},"image":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/#primaryimage"},"thumbnailUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/bioithas_featured_.jpg","datePublished":"2020-05-22T09:26:22+00:00","dateModified":"2025-11-25T13:23:15+00:00","description":"La Esclerosis M\u00faltiple (EM) es una enfermedad cr\u00f3nica del sistema nervioso central. La EM afecta a m\u00e1s de 2,5 millones de personas en el mundo, siendo uno de los trastornos neurol\u00f3gicos m\u00e1s comunes en adultos j\u00f3venes. Por otro lado, produce un alto impacto socioecon\u00f3mico...","breadcrumb":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/#primaryimage","url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/bioithas_featured_.jpg","contentUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/bioithas_featured_.jpg","width":800,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/bioithas-sclerotest\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/evolutioneurope.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Success stories","item":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/"},{"@type":"ListItem","position":3,"name":"Bioithas \u2013 ScleroTest"}]},{"@type":"WebSite","@id":"https:\/\/evolutioneurope.eu\/es\/#website","url":"https:\/\/evolutioneurope.eu\/es\/","name":"evolution-europe","description":"","publisher":{"@id":"https:\/\/evolutioneurope.eu\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/evolutioneurope.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/evolutioneurope.eu\/es\/#organization","name":"Evolution Europe","url":"https:\/\/evolutioneurope.eu\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/evolutioneurope.eu\/es\/#\/schema\/logo\/image\/","url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/04\/social-share-image-2000x1600-1.jpg","contentUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/04\/social-share-image-2000x1600-1.jpg","width":2000,"height":1600,"caption":"Evolution Europe"},"image":{"@id":"https:\/\/evolutioneurope.eu\/es\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/success-stories\/2740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/success-stories"}],"about":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/types\/success-stories"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/media\/2292"}],"wp:attachment":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/media?parent=2740"}],"wp:term":[{"taxonomy":"flags","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/flags?post=2740"},{"taxonomy":"program","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/program?post=2740"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/sector?post=2740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}